Morgan Stanley Knock-Out GNMSF/ DE000ME9QLL0 /
2024-04-25 9:15:10 PM | Chg.- | Bid10:00:35 PM | Ask10:00:35 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.001EUR | - | - Bid Size: - |
- Ask Size: - |
Genmab A/S | 1,922.171 - | 2078-12-31 | Call |
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
2023-10-17
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
2023-09-25
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
2023-09-04
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
2021-10-19
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
2021-09-20
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
2021-07-21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
GlobeNewswire
2021-06-22
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumu...
GlobeNewswire
2021-05-21
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab...
GlobeNewswire
2021-04-20
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021